From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cells
At the end of november 2013, Science magazine chose the advances made in Cancer Immunotherapy as the breakthrough of the year (Couzin-Frankel, 2013). The dramatic clinical outcome of patients treated with chimeric antigen receptor (CAR) T cells has been described as one of the major turning points of cancer therapy. In the framework of the annual issue of the journal of Human Gene Therapy that is dedicated to personal perspectives by scientists who have pioneered the field, I am honored to represent the members of my lab who have worked alongside me in establishing the CAR T cell approach (which we nicknamed “T-bodies”) and taken it from its initial proof of concept, through experimental animal studies, until its recent successful testing by our fellow clinicians in cancer patients.
Chronicle of CAR Invention At the end of November 2013, Science magazine chose the advances made in Cancer Immunotherapy as the breakthrough of the year (Couzin-Frankel, 2013). The dramatic clinical outcome of patients treated with chimeric antigen receptor (CAR) T cells has been described as one of the major turning points of cancer therapy. In the framework of the annual issue of the journal of Human Gene Therapy that is dedicated to personal perspectives by scientists who have pioneered the field, I am honored to represent the members of my lab who have worked alongside me in…
related reading
- Teaching an old dog new tricks: next-generation CAR T cells | British Journal of Cancernature.com
- Medicine's Endgamenotboring.co
- 癌症治療的海豹特種部隊 淺談CAR-T細胞治療法::台灣癌症基金會canceraway.org.tw
- The blood cancer that became solvableworksinprogress.news
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerationsncbi.nlm.nih.gov
- Immunotherapy for Cancer - NCIcancer.gov
- What is tumor-infiltrating lymphocyte (TIL) therapy? | UT MD Andersonmdanderson.org
- Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designationmed.stanford.edu
- Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variablespmc.ncbi.nlm.nih.gov
- Optimization of velocity receptor transduction in CAR T cells | bioRxivbiorxiv.org